Skip to main content
SpringerLink
Log in

Therapieoptionen beim Prostatakarzinom

  • Chapter
Prostatakarzinom

Part of the book series: Optimierte Arzeimitteltherapie ((ARZNEIMITTELTH.))

  • 74 Accesses

Zusammenfassung

Die Indikation zur Hormonablation (i.e. Blockade des Testosterons, Androgenblackade) bei Patientin mit einem PCA wird oft bei verschiedenen Stadien gestelt. Bei einem fortgeschrittenen Prostatakarzinom führt sie in 80–90% zu einer Remission und resultiert in einem progreesionsfrein Überleben von 12 bis 33 Monaten (Denis u. Murphy 1993). Nach dieser Zeit ist das PCA oft hormonrekraftär geworden, sodass das Gesamtüberleben nach Beginn der AB bei 23 bis 37 Monaten liegt. Bereits 1895 dokumentierte White als erster die Wiksamkeit der Kastration als Form der Androgenblockade bei 11 Patienten mit einer BPH (White 1895). 1935 gelang David und Mitarbeitern die Isolierung des Testosterons. Aber erst 1941 beschrieben Huggins und Hodges die Androgenablation als Theraphie beim fortgeschrittenen PCA (Burrows 1949;Huggins u. Hodges 1941).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 19.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 39.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abell FL, Wilkes JD, Divers L. Oral cyclophosphamide (CTX) for hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1995; 14: abstract 646

    Google Scholar 

  • Amato RJ, Ellerhorst J, Bui C et al. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol 1995; 1: 168

    Article  CAS  PubMed  Google Scholar 

  • Benson R u. Hartley-Asp B Mechanism of action and clinical uses of estramustine. Cancer Invest 8: 375; 1990

    Article  CAS  PubMed  Google Scholar 

  • Biedermann B, Pless M, Herrmann R. Chemotherapie beim hormonrefraktären Prostatakarzinom. Dtsch. Med. Wschr. 1999; 124: 874

    Article  CAS  Google Scholar 

  • Blumenstein B, Crawford ED, Saiers JH et al. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group Study. J Urol 1993; 150: 411

    CAS  PubMed  Google Scholar 

  • Casciano R, Petrylak D, Neugut AI et al. Systematic review of chemotherapy efficiacy from controlled trials in hormone-refractory prostate cancer (HRPC) patients. Proc Am Soc Clin Oncol 2001; 20: 2428

    Google Scholar 

  • Catalona WJ. Management of prostate cancer. N Engl J Med 1994; 331: 996

    Article  CAS  PubMed  Google Scholar 

  • Dawson NA. Treatment of progressive metastatic prostate cancer. Oncology 1993;7:17

    CAS  PubMed  Google Scholar 

  • Dawson NA. Apples and oranges: Building a consensus for standardised eligibility criteria and end points in prostate cancer clinical trials. J Clin Oncol 1998;16: 3398

    CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Panopoulos C, Bamia C et al. Oral estramustine and oral etoposide for hormone refractory prostate cancer. Urology 1997; 50: 754

    Article  CAS  PubMed  Google Scholar 

  • diSant’Agnese PA Neutoendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992; 70; 254

    Article  Google Scholar 

  • Ellerhorst JS, Tu SM, Amato RJ. A phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 1997; 3: 2371

    Google Scholar 

  • Falcone A, Antonuzzo A, Danesi R et al. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 1999; 86: 470

    Article  CAS  PubMed  Google Scholar 

  • Ferro MA, Gillatt D, Symes MO et al. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate specific antigen to monitor response. Urology 1989; 34: 134

    Article  CAS  PubMed  Google Scholar 

  • Fournier G. Treatment of hormone-refractory prostate carcinoma: Eur Urol 1996;30 (suppl. 1): 32

    PubMed  Google Scholar 

  • Fowler JE, Pandey P, Seaver LE et al. Prostate specific antigen after gonadal withdrawal and deferred flutamide treatment. J Urol 1995; 154: 448

    Article  PubMed  Google Scholar 

  • Fowler JE u. Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126: 372

    PubMed  Google Scholar 

  • Hartley-Asp B u. Kruse E. Nuclear protein matrix as a target for estramustine induced cell death. Prostate 1986; 9: 387

    Article  CAS  PubMed  Google Scholar 

  • Heidenreich A, Knoblauch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Ural 2001a; 39: 121

    Article  CAS  Google Scholar 

  • Heidenreich A, Hofmann R, Engelmann UH. The use of bisphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Ural 2001b; 165: 136–40

    Article  CAS  Google Scholar 

  • Horton J, Rosenbaum C, Cummings FJ. Tamoxifen in advanced prostate cancer: an ECOG pilot study. Prostate 1988; 12: 173

    Article  CAS  PubMed  Google Scholar 

  • Huan SD, Stewart DJ, Aitken SE et al. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am J Clin Oncol 1999; 22: 471

    Article  CAS  PubMed  Google Scholar 

  • Hudes GR, Greenberg R, Krigel RL et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992; 10: 1754

    CAS  PubMed  Google Scholar 

  • Hudes G, Nathan F, Khater C. Phase II trial of 96 hour-paclitaxel plus estramustine phosphate in metastatic hormone refractory prostate cancer. J Clin Oncol 1997b; 15: 156

    Google Scholar 

  • Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol 1997a; 15: 13

    CAS  Google Scholar 

  • Hudes G, Einhorn L, Ross E et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999; 17; 3160

    CAS  PubMed  Google Scholar 

  • Hussein M, Wolf M, Marshall E et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. Clin Oncol 1994; 12: 1868

    Google Scholar 

  • Iversen P, Rasmussen F, Asmussen C et al. Estramustine phosphate versus plazebo as a second-line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. J Urol 1997; 157: 929

    Article  CAS  PubMed  Google Scholar 

  • Joyce R, Fenton MA, Rode P et al. High-dose bicalutamidefor androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1997; 159: 149

    Article  Google Scholar 

  • Kantoff PW, Halabi S, Conaway M, Picus J et al. Hydrocortisone with and without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B9182 study. J Clin Oncol 1996; 17: 2506

    Google Scholar 

  • Kelly WK, Scher HI, Mazumadar M et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993a; 11: 607

    CAS  Google Scholar 

  • Kelly WK u. Scher HI Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Urol 1993b; 149; 607

    CAS  Google Scholar 

  • Kelly WK. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol 1998; 34 (suppl 4): 18

    Article  PubMed  Google Scholar 

  • Klugo RC, Farah RN, Cerny JC. Bilateral orchiectomy for carcinoma of the prostate: response of serum testosterone and clinical response to estrogen therapy. Urology 1981; 17:49

    Article  CAS  PubMed  Google Scholar 

  • Kreis W. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest 1995; 13: 296

    Article  CAS  PubMed  Google Scholar 

  • Kreis W, Budman DR, Felten J et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999; 10: 33

    Article  CAS  PubMed  Google Scholar 

  • Laurie JA, Hahn RG, Therneau TM. Chemotherapy for hormonally refractory advanced prostate cancer: a comparison of combined versus sequential treatment with mitomycin C, doxorubicin and fluorouracil. Cancer 1992; 69: 1440

    Article  CAS  PubMed  Google Scholar 

  • Mahler C u. Denis L. Hormone refractory disease. Semin Surg Oncol 1995; 11:77

    Article  CAS  PubMed  Google Scholar 

  • Maulard-Dardux C, Dufour B, Hennequin C et al. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 1997; 77: 1144

    Article  Google Scholar 

  • Oh WK u. Kantoff PW. Management of hormone refractory prostate cancer: current status and future prospects. J Urol 1998; 160: 1220

    Article  CAS  PubMed  Google Scholar 

  • Orlando M, Chacon M, Salum G et al. Low-dose oral fosfestrol is highly active in hormone-refractory prostate cancer. Ann Oncol 2000; 11: 177

    Article  CAS  PubMed  Google Scholar 

  • Oudard S, Banu E, Beuzeboc P et al. Phase II randomised trial of docetaxel, estramustine and prednisone - two schedules - versus mitoxantron and prednisone in patients with hormone-refractory prostate cancer. Ann Oncol 2002; 13 (Supp): 3250P

    Google Scholar 

  • Petrylak DP, Macarthur RB, O’Connor J et al. Phase I trial of docetaxel with estramustine in androgen independent prostate cancer. J Clin Oncol 1999; 17: 958

    CAS  PubMed  Google Scholar 

  • Petrylak DP Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999; 54 (suppl 6a): 31

    Article  Google Scholar 

  • Pienta KJ, Redman B, Hussein M et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005

    Google Scholar 

  • Pienta KJ, Naik H, Lehr JE. Effect of estramustine, etoposide and taxol on prostate cancer cell growth in vitro and in vivo. Urology 1996; 48: 164

    Article  CAS  PubMed  Google Scholar 

  • Raghavan D, Cox K, Pearson BS et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 1993; 72: 625

    Article  CAS  PubMed  Google Scholar 

  • Rochlitz CF, Damon LE, Russi MB et al. Cytotoxicity of Ketoconazole in malignant cell lines. Cancer Chemother Pharmacol 1988; 21: 319

    Article  CAS  PubMed  Google Scholar 

  • Saad F, Gleason DM, Murray R et al. A randomised, plazebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458

    Article  CAS  PubMed  Google Scholar 

  • Sartor O, Cooper M, Weinberger M et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of „hormone-refractory“ prostate cancer. J Natl Cancer Inst 1994; 86; 222

    Article  CAS  PubMed  Google Scholar 

  • Schellhammer P, Venner P, Haas G et al. Prostate specific antigen decreases after withdrawal of androgen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157:1731

    Article  CAS  PubMed  Google Scholar 

  • Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46: 142

    Article  CAS  PubMed  Google Scholar 

  • Scher HI, Fossa S. Prostate cancer in the era of prostate-specific antigen. Curr Opin Oncol 1995; 7: 281

    Article  CAS  PubMed  Google Scholar 

  • Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer. Defining the target. J Natl Cancer Inst. 1996; 88: 1623

    Article  CAS  PubMed  Google Scholar 

  • Scher HI, Liebertz C, Kelly WK et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15: 2928

    Google Scholar 

  • Scholz MC, Guess B, Barrios F et al. Low-dose single-agent weekly docetaxel is effective and well tolerated in elderly men with prostate cancer. Proc Am Soc Clin Oncol 2001; 20: abstract 2441

    Google Scholar 

  • Seidmann AD, Scher HI, Petrylak D et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostate cancer. J Urol 1992; 147: 931

    Google Scholar 

  • Small EJ, Srinivas S, Egan B et al. Doxorubicin and dose escalated cyclophosphamid with granulocyte colony-stimalating factor for the treatment for hormone-resistant prostate cancer. J Clin Oncol 1996; 14: 1617

    CAS  PubMed  Google Scholar 

  • Small EJ, Baron AD, Fippin L et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 159: 1204

    Google Scholar 

  • Small EJ, McMillan A, Meyer M et al. Serum prostate-antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points and survival. J Clin Oncol 2001; 19: 1304

    CAS  PubMed  Google Scholar 

  • Smith DC, Dunn RL, Srawderman MS et al. Change in serum prostate-.specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998; 16: 1835

    CAS  PubMed  Google Scholar 

  • Stein CA. Mechanism of action of taxanes in prostate cancer. Semin Oncol 1999; 26 (suppl 17): 3

    CAS  PubMed  Google Scholar 

  • Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a canadian randomised trial with palliative end points. J Clin Oncol 1996; 14: 1756

    CAS  PubMed  Google Scholar 

  • Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic prostate cancer. N Engl J Med 1995; 332: 1393

    Article  CAS  PubMed  Google Scholar 

  • Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Onol 1993; 11: 2167

    Google Scholar 

  • Veronesi A, Re Gl, Foladore S et al. Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. A phase ii study. North Eastern Italian Oncology Group. Eur Urol 1996; 29: 434

    CAS  PubMed  Google Scholar 

  • Vogelzang NJ, Crawford ED, Zietman A. Current clinical trial design issues in hormone refractory prostate cancer. Cancer 1998; 82: 2093

    Google Scholar 

  • Vogelzang NJ. One hundred thirteen men with hormone-refractory prostate cancer died today. J Clin Oncol 1996; 14: 1753

    CAS  PubMed  Google Scholar 

  • Von Roemeling R, Fisher HA, Horton J et al. Daily oral cyclophosphamide is effective in hormone-refractory prostate cancer: a PH-I/II pilot study. Proc Am Soc Clin Oncol 1995; 11: abstract 665

    Google Scholar 

  • Wilding G. Endocrine control of prostate cancer. Cancer Sury 1995; 23: 43

    CAS  Google Scholar 

  • Wolff JM. Das hormonrefraktäre Prostatakarzinom. Uni-Med Verlag, Bremen 2001

    Google Scholar 

  • Yagoda A u. Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 1993; 71 (suppl 3): 1098

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Caritas Krankenhaus Bad Mergentheim, Uhlandstr. 7, 97980, Bad Mergentheim, Deutschland

    Prof. Dr. med. Johannes Wolff

  2. Krankenhaus Barmherzige Brüder München, Romanstr. 93, 80639, München, Deutschland

    Prof. Dr. med. Jens Altwein

Authors
  1. Prof. Dr. med. Johannes Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Jens Altwein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Wolff, J., Altwein, J. (2004). Therapieoptionen beim Prostatakarzinom. In: Prostatakarzinom. Optimierte Arzeimitteltherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18822-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18822-0_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20913-3

  • Online ISBN: 978-3-642-18822-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation